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Canine Symposium 
Cancer in Dogs 
The 28th Annual Canine Sympo­sium was held January 31 . 1998 at VHUP. The e ent was organ­
ized wi th th help of the School's Mari 
Lowe Center for Comparative Oncology 
and featured a series of presentations on 
Cane r in Dogs. 




The words cancer and growth are bru­
tally intertwined. But they are also con­
nected in several positive ways, said Dr. 
Narayan G. Avadhani . professor of bio­
chemistry at th School. In recent years, 
cancer has m t tremendous growth in re­
search, knowledge , technology and treat­
ment modal ities . Dr. Avadhani presented 
Penn 's Mari Lowe Center for Compara­
tive Oncology. wh ich conducts extensive 
cancer research and c1 inicaJ programs. 
Cancer is a g n tic disease, Dr. 
Avadhan i xplained. Yet cancer is in­
herited in only fi ve percent of cases. The 
re t spon taneously arise followi ng a pri ­
mary DNA lesion that occurs during the 
life of an individual. "It is this 9S percent 
of the populat ion that's go ing to be ex­
tremely important for understanding can­
cer in both humans and animals. 
"Animals are exposed to the same en­
vi ronment and some of the same putative 
causal factors that we are: ' he said. 
With these issues in mind, the Center, 
which is supported primarily through in­
dividual and found aLlon contributions, 
has created a state-of-the-art clinical on­
cology service at VHUP and today trains 
veterinary oncologists, conducts 
multidisciplinary re 'earch and supports 
outside cancer research. Since its estab­
lishment four years ago, said Dr. 
Avadhani, who heads the Center, the 
number of canine cancer patients at 
VHUP bas more than doubled to some 




What exactly is cancer? The language 
used to discuss cancer and its Lreatment 
is composed of many words that are not 
part of everyday conversation. Dr. Kim 
Cronin introduced some of the basic ter­
minology that veterinary cancer special­
ists use and also discussed the early 
warning signs of cancer to help the sym­
posium audience prepare for the lectu res 
that would follow. 
The early warning signs of cancer in 
small animals are similar to the seven 
warning signs of cancer in people used 
by the American Cancer Society. The 
signs range from: an abnormal swelling 
that persists or continues to grow, a sore 
that does not heal, weight loss, bleeding 
or a discharge from any body opening, 
reluctance to exercise, a loss of stamina 
or difficulty breathing, urinating or def­
ecating. Even subtle changes , such as 
sleeping more, not playing as much and 
lack of desire to interact may indicate the 
need for a veterinary evaluation to deter­
mine if additional tests are necessary. 
The term neoplasia means new 
growth and is used interchangeably with 
cancer. It takes about a billion cells, or 
thirty doublings, before we can actually 
see a tumor. When rapidly dividing can­
cer cells invade normal tissue the cancer 
becomes malignant. Malignant cancers 
can metastasize - spread to other parts 
of the body. During metastasis the cancer 
cells move through the blood stream or 
lymphatic vessels and may settle in tis­
sues distant from their origin. The loca­
tion where the tumor grew before 
metastasizing is called the primary site. 
Benign tumors are not usually invasive 
and do not metastasize. 
The lungs and lymph nodes are the 
most common sites for tumor metastasis, 
however, there are many types of cancer 
that selectively spread to other parts of 
the body. The way a tumor grows and 
spreads is called its biologic behavior. 
The biologic behavior of a tumor deter­
mines what tests will be performed, how 
the animal will be treated therapeutically 
and what the probable outcome will be. 
There are many unique terms u 'ed to 
describe the procedures involved in the 
clinical workup of an animal with cancer. 
An aspiration is when a needle attached 
to a syringe is inserted into the tumor 
and the plunger on the syringe is drawn 
back to suction a few cells from the mass 
for microscopic analysis . Cytology refers 
to the examination of the cells collected 
by aspirate . biopsy involves the surgi­
cal removal of a small piece of tissue and 
examining it under the microscope. 
Grading of tumors is accomplished by 
characterizing the tumor cells usi ng the 
microscope. Tumors are assigned into 
high , intermediate and low grades based 
on microscopic evaluation. High grade 
tumors tend to be very aggressive, they 
spread early and are difficult to treat. 
Low grade tumors are exactly the oppo­
site . Staging is the evaluation of the ex­
tent of the tumor and the prognosis is the 
expected outcome for that tumor. A pro­
tocol is the overall treatment plan , the 
drugs used , how often as well as the 
number of times repeated. Finally, when 
the bone marrow is no longer able to 
produce normal cells the patient loses the 
ability to fight infection and sepsis re­
sults. Sepsis is an overwhelming sys­
temic infection. Recognizing the early 
warning signs of cancer may lead to 
early detection and significantly in­
creases the likelihood of success ful 
treatment. 
M.R. 




Imaging techniques are indi spensable 
in the management of cancer in domestic 
animals. Dr. Jeffrey A. Wortman, associ­
ate professor of radiology at the School , 
discussed the applications of various im­
aging modalities in diagnosing cancers, 
assessing prognoses, planning treatments 
and monitoring disease response . 
Diagnostic imaging techniques, such 
as radiography - or "x-rays," are used 
for cancer screening, detection , staging 
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and surveill ance. Screening tests are em­
ployed to detect cancer in a population 
prior to the onset of clinical signs; unlike 
in people, in whom screening tests like 
routine mammography are often per­
formed, these tests are infrequently done 
in animals. Imaging studies are routinely 
used to detect the presence of neoplasia 
in clinically-affected animals. These 
studies have variable sensitivi ties and 
specificities for diagnosing different tu­
mor types; additional tests like tissue bi­
opsy are often added to augment imaging 
studies. 
Imaging tests also serve in staging of 
cancers. Once the diagnosis is confi rmed 
by histopathology, such imaging diag­
nostics as thoracic radiography can then 
be used to detect tumor metastasis from 
primary sites, such as bone; these "mets" 
show up as radiopaque (white) nodules. 
Thi s infonnation is important in affixing 
prognosis and planning treatments like 
surgery, radiation therapy and chemo­
therapy. " If the cancer has spread: ' said 
Dr. Wortman, " this indicates that it 's ag­
gressive and will be more difficult to 
treat and cure." 
ollow-up imaging studies can then be 
incorporated into disease surveillance to 
chronicle disease regression , progression , 
relapse, and treatment complications. 
The imaging methods that are particu­
larly efficacious in veterinary oncology 
include radiography +/- contrast (i.e. io­
dinated agents) ultrasound, x-ray com­
puted tomography (CT), magnetic 
resonance imaging (MRI) and nuclear 
scintigraphy (scans). The choice of imag­
ing study, Dr. Wortman explained, "de­
pends on many things, like the patient 
hi story and (tentative) diagnosi s, which 
will give us some idea of the nature of 
the cancer and its biological behavior." 
The choice also depends on what infor­
mation is being sought, availability and 
quality of the imaging technology and 
expertise of the veterinarian interpreting 
the study. 
Ultrasonography, an imaging tech­
nique in which deep structures of the 
body are visualized by recording the re­
flection s of sound waves directed into 
the tissues, enables one to view masses 
that mayor may not be externally pal­
pable. It can also be used to safely direct 
biopsy instruments to internal sites so 
ti ssue samples can be obtained for pa­
thology. Likewise, a CT scan or an MRJ 
may elucidate a brain tumor that would 
not be apparent on skull radiographs. The 
availability of imaging modalities in vet­
erinary medicine is variable. Radiogra­
phy, including contrast techniques, is 
ubiquitous throughout pri vate veterinary 
practice, said Dr. Wortman, and ultra­
sound is steadily becoming more acces­
sible. But more sophisticated studies, 
like CT and MRI, are less accessible to 
animal patients. 
Whatever imaging testes) one selects 
to screen for. diagnose, stage or monitor 
cancer, Dr. Wortman adv ised, one should 
maximize the fitness of the test by using 
proper technique. In radiography this in­
cludes correct body positioning and fi lm 
exposure, and use of contrast agents 
where appropriate. 
" You need to be aware of the limita­
tions of a specific test and try to expand 
on the test in order to accurate ly make 
the diagnosi s." 
I e. 
Breed Related Callcers 
Many cancers have been found to 
have a breed predilection . Dr. Michael H. 
Goldschmidt, professor of pathology at 
the School and head of the Surgical Pa­
thology Service of the Laboratory of Pa­
thology and Toxicology, showed 
examples of specific cancers in the dog 
and the breeds most commonly affected. 
Dr. Goldschmidt cited a study con­
ducted in the 1960's in the USA that esti­
mated tumor incidence at about 1. 100 
cases per 100,000 dogs per year. The 
Laboratory of Pathology had developed 
an extensive computerized database of 
canine cases ; in the decade preceding 
1995 over 130,000 cases in dogs were 
submitted to the Surgical Pathology Ser­
vice for diagnosi s. Most tumors in these 
dogs were from the skin , oral cavity, 
mammary gland and male genitalia. Be­
cause of the large size of the database it 
I 
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was often possible to calculate the breed 
risk for commonly diagnosed tumors. 
An example of this wa~ mammary tu­
mors. Benign mammary tumors, seen 
clinically as well encapsulated masses of 
varying size and consistency on palpa­
tion, were found to have a higher predi­
lection for small breeds of dogs snch as 
the miniature poodle, Yorkshire terrier, 
Chihuahua and Maltese_ Malignant 
mammary tumors, seen clinicall y as in­
vasive, inflamed, ulcerated masses with 
lymphatic invasion in some cases, had a 
higher predilection in the English setter. 
Chihuahua, miniature poodle and Afghan 
hound. Many breeds at dec reased risk for 
developing mammary tumors, such as 
the golden retriever. Rottweiler and 
boxer were at high risk for developing 
soft ti ssue and mesenchymal tumors. 
The incidence and types of tumors are 
breed related and probably controlled by 
a single or multiple genes. An example 
given was the German shepherd which is 
predisposed to developing nodul ar 
dermatofibrosis, a syndrome that is com­
pri sed of a three tumor; multiple dermal 
fi bromas (multiple fi nn masses in the 
skin), renal cystadenocarcinomas (malig­
nant cystic epitheli al tumors throughout 
the kidneys), and in females uterine 
leiomyomas (benign tumors of the 
smooth muscle). 
Dr. Goldschmidt also illustrated the 
increased and decreased breed risks asso­
ciated with two speci fic skin tumors , in­
cluding infundibular keratinizing 
acanthoma, to which the Norwegian 
elkhound is highly predisposed with a 
rel ative ri sk of 29. and tri choblastoma, to 
which the Keny blue terrier is predis­
posed with a relative risk of 12. 
Otiler specific tumors with high breed 
risks were also discussed. These included : 
• Trichoepithelioma: basset hound 
• Pilomaticoma: Kerry blue terrier 
• Ceruminous adenoma: cocker spaniel 
• Anal sac gland carcinoma: English 
cocker spani el 
• Subungual squamous cell carcinoma: 
giant schnauzer and Gordon setter 
• Subungual malignant melanoma: 
Scottish terri er 
(contin ued on page 22) 
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• Melanocytoma: Vizs la and miniature 
schnauzer 
• Liposa rcoma: Shelland ~heepdog 
• Mast cell tumor: boxer and pug 
• Cutaneous plasmacyt 	ma: cock r 
\paniel 
Dr. Goldschmidt concluded that by 
selecting for the specific extern al fea­
tures of a dog. its phenotype, we are se­
lecting spec ific genes, which make that 
breed more or less susceplib le to devel­
oping a specific cancer. 
Ie 
Cancer Treatment Options 
When it com s to treating cancer, 
quant ity and quali ty should go hand-in­
hand . Dr. Karin Sorcnmo, ass is tant pro­
fessor of oncolog at the School , sa id 
that cancer therapy is best governed by 
attempts to prolong l ife within the realm 
of maintaining reasonable qual ity of ex­
istence. "We try to maintain the highest 
degree of function and take as few risks 
for seriou complications as poss ible" 
when planning cancer treatment proto­
cols, she sa id. 
Several factors infl uence cancer treat­
ment decisions . Most importan t are the 
tu mor type, biological behavior and stag­
ing. Malignant tumors are characterized 
by local invasion +1- di stant metastasis. 
Highly malignant (high grade) tumors 
ofte n have me tas lasiz d by the time the 
pati en t's cancer is diagnosed. For high­
grade tumors , aggressive treatment com­
bini ng surgery and chel lotherapy is 
often warranted even if metastases are 
not yet detectable radiographically. T he 
goal then is not typically to cure, but 
rather to prolong su rvival by ~ lowing 
di sease progress ion and to provide pal­
liation. O n the other hand, tumors that 
are locally invasive bu t less likely to 
spread offer better prognoses and are of­
ten treated effecti vel y with surgery andl 
or radiation therapy. 
The patien t's overall health status 
plays a major role in lherap choices. 
Concurrent diseases should be attended 
to and the patient evaluated for its ability 
to tolerate cancer treatme nt. Life expect­
anc y should be taken into consideration 
as wel l; for a slow-growing tumor in an 
older dog, for example , the treatment 
drawbacks may outpace the potential 
benefi ts . 
Owner fac tors also impact medical 
decisions because treati ng cancer re­
quires the owner's money, commitment 
and emotional resilience. 
The three principal cancer treatment 
modalities are surgery, radiation therapy 
and chemotherapy. Su rgery has two 
functions in cancer management: to ob­
tain tissue biopsies for definit ive di ag no­
sis and to excise les ions completely. 
Biopsy provides information about the 
mitotic index and vascularity of the tu­
mor, both of which are increased in rap­
idly-growing masses. Local lymph nodes 
can also be biopsied to detect evidence 
of tumor spreading. 
Tumor excision is perfonned for both 
curative and - in the case of painful tu­
mors like osteosarcomas - pall iative 
reasons. Tumors are resected with wide 
margins; the objective is to obtain 
"clean" or cancer-free borders, thereby 
minimizing the likelihood of local recur­
rence. O nce the lesion is e cised, the 
borders are examined histologically for 
the presence of neoplastic cells . 
Radiation therapy is a suitable alte r­
native to radical surgery for tumors in 
certain locations, such as the head or 
legs. Rad iation is also important for ad­
junctive treatment of tumors that are not 
completely resectab le, as weJl as for lo­
cally-invasive tumors like nasal carcino­
mas, for which surgery alone is usually 
not curati ve. As an adjunct to su rgery, ra­
diation therapy is effective in steril izi ng 
the borders. If the borders are clean, the 
mai n concern then becomes distant meta ­
stasi s. 
C hemotherapy is often combined with 
surgery or radiation therapy to treat high­
grade tumors that are likely to metasta­
size. In addition, it 's the treatment of 
choice for multicentric cancers like leu­
kemia or lymphosarcoma..:hemotherapy 
strikes rapidly-dividing celts, which, in 
addition to cancer cells, include normal 
cells of the bone marrow, oral mucosa 
and G .l. tract. Many owners fear poten­
tial chemotherapy side effects . However, 
those seen in people, such as hair loss 
and nausea, are not typica lly experienced 
by dogs. Because most breeds do not 
have continuously-growing ha ir, the hai r 
folli cular cells are not affected by che­
motherapy. More importantly, the objec­
tive for most canine cancer patien ts is to 
prolong life rather than establish a cure. 
Therefore, lower doses and fewer drug 
co mbinations are used. 
" If we treat aggressively and cause se­
rious complications in these normal tis­
sues, all the while knowing we are not 
going to cure the animal," Dr. Sorenmo 
explained, "then we probably haven ' t 
done that animal a favor." 
Veterinarians administer the same 
chemotherapy drugs used in human on­
cology. The drugs are given orally, intra­
venously or subcutaneously. Ex tensive 
owner cooperation is necessary in com­
plying with strict and sometimes rigor­
ous treatment schedules. But the returns 
can be weJl worth the effort. Dr. 
Sorenmo pointed out that chemotherapy 
extends the average lymphosarcoma sur­
vival time from just two months (un­
treated) to a year; ten to 15 percent of 
these cases never relapse. For osteosar­
coma, following surgery with chemo­
therapy doubles the survi val time over 
amputation alone. 
In designing a cancer treatment proto­
col utilizing any or all of the aforemen­
tioned options, one must first define the 
treatment goal based on a realisti c prog­
nosis . T his determines acceptable levels 
of owner resources spent and patient dis­
comfort tolerated . D r. Sorenmo cau­
tioned: "The treatment should not be 
worse than the disease itself." 
i.e. 
Quality of Life Issues for 

Cani1le Cancer Patients 

"Quality of life concerns are impor­
tant to ve teri narians who want their pa­
tients to feel good, they are important to 
pet owners because pet;; are often consid­
ered family members, and quality of life 
is certainly important to our patients" ex­
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plained Dr. Lillian Duda, lecturer in ra· 
diation oncology. 
Once a diagnosis of cancer is made , 
tbe decision to pursue treatment hinges 
on the determination of the quality of life 
that can be expected for the animal from 
that point onward. The veterinarian can 
help the pet owner feel comfortable talk­
ing about the many issues invol ved, and 
they must work together toward a com­
mon goal. It is something that should 
also be discussed between family mem­
bers and fri ends because the malle I' is 
both personal and emotionally charged. 
The main goal in cancer treatment is 
to secure a high quality of life for as long 
as possible. A pet may be kept alive in 
the hospital using supportive measures 
such as oxygen and intravenous flu ids, 
but, it may not be acceptable to do so if 
there is no hope of improving the pet 
enough that it can go home. Quality of 
life issues are more easily overlooked 
and more diffic ult to assess than quantity 
of life issues. There must be a balance 
between both. The veterinarian can help 
by remaining objective and providing in­
formation about the cancer and the ef­
fects of treatments on the animal. 
However, the veterinarian depends on 
the owner to report how their pet is feel­
ing and behaving. 
The side effects of cancer therapy are 
numerous and vary greatly bet ween pa­
tients. In general, it is not acceptable to 
expect the al1imal to suffer side effects 
from the treatmcnt without a good 
chance of a belicf life. The Animal Medi­
cal Center in New York City has devel­
oped a scale to assess the overall quality 
of life for dogs undergoing cancer treat­
ment. They measure the dog's ability to 
carry out normal daily activities using 
five parameters. Eating is one of the pa­
rameters that is measured. As their qual­
ity of life begins to decrease, dogs will 
often show changes in their eating habits 
or may have a general loss of appetite, 
some other parameters are alertness, 
body condition ~. tind activity level. This 
scoring method makes the difficult task 
of assess ing the dog's condition more 
objective and provides useful medica l in­
formation. Studies have shown that indi­
viduals scoring closer to normal tend to 
do better overall. 
Quality of life means something differ­
ent to each pet owner. People are asked to 
come up wi th and write down their per­
sonal minimum level of acceptable qual­
ity or life for their pet before it receives 
treatment. This is done to help them an­
ticipate, and thereby prepare for some of 
the important dec isions they may need to 
make. If the unanimous goal is to prolong 
a quality life and to minimize suffering 
then euthanasia is sometimes the only op­
tion remaining. Euthanasia is a humane 
and responsible decision - a final 
therapy aJlowing the pet to be released 
from pain and suffering. 
/'vf.R .. 
Nutritiollal Needs of 

Canine Cancer Patients 

Animals with seri ous chronic illness 
are often malnourished. One of the pri­
mary reasons this occurs is because their 
appetites are impaired by the illness and 
oftentimes the on ly food they accept ­
table food - is nutri tionally inadequate. 
This may not be cri ti cal for short periods 
of time, but. when treatments ex tend for 
weeks or even months there can be seri­
ous effects on the animal 's health related 
to malnourishment. "1 like to tell people 
it is their job to find something the ir dog 
will eat adequate amounts of consistently 
and I can bu ild a balanced diet around 
it," said Dr. Kathryn Michel. ass istan t 
professor of nutrition . Cancer not only 
affects the patient's quality of life , but, 
can also impair their abi li ty to tolerate 
cancer treatments. Meeting the unique 
needs of patients undergoing cancer 
therapy is augmented by providi ng ad­
equate nutrition, however, dietary 
therapy in this context is considered sup­
portive rather than primary care. 
Dr. M ichel reviewed the six basic 
classes of nutrients. "I know that we 
don ' t normally think of water as a nutri­
ent but really it is the most essential nu­
tr ient there is . An animal will die of 
dehydration in a much shorter time than 
it will die from starvation." After water, 
CA.rTll rE ::ilMP():;lUM~ 
the body must have nutrients that p ro­
vide energy sllch as carbohydrates. fats 
and protein. Protein not on ly suppl ies 
calories, it is also the source of amjno ac­
ids which the body uses to make new 
proteins. Micronutrients are also deri ved 
from the minerals and vitamins in the 
diet. A dog with cancer will require wa­
ter, adequate calories, p rotei n, minerals 
and vitLU11ins, however, cancer causes 
changes in normal metabolism that are 
not overcome by supplying calories and 
nutrients. At this lime the spec ific nutr i­
tional requiremenb for dogs wi th cancer 
have not been established. 
Cancer therapies that reduce the 
chances of deleteriolls side effects are al­
ways sought, but, they are not always 
completely successful. Some patients 
may have nausea. vomiting or diarrhea 
as a result of their trea tment. If an animal 
associates side effects such as nausea 
wi lh the act of eating they may stop eat­
ing for that reason. This phenomenon is 
termed a learned food aversion and pre­
sents qu ite a challenge when we try to 
feed these animals. An important part of 
nursing a dog or cat th rough an illness is 
coaxed feeding. It is very important not 
to push food on an animal that does not 
want to eat. [t is best to wa it until the pet 
is comfortab le and not stressed before 
presenting food. Do not attempt feed ing 
right after changing bandages or giving 
medications . It may be best to feed them 
cold food directly from the refrigerator, 
as it will not have much taste or aroma. 
Drugs may be useLi to reduce nausea as a 
short term approach if the dog~ are hav­
ing gastroi ntesti nal "ide effects . Appeti te 
stimulan ts are most useful in convales­
cent ani mals to "j ump-start" their appe­
tites. but , rea lly have very limited 
application. They are not intended for 
long term use. If the dog shows some in­
terest in food try feeding novel food 
items or offer food in a di fferent setting 
or at differen t l imes. You can also divide 
the day's food up into a number of small 
meals instead of one or two large ones. 
Some patients may benefi t from nutri­
tional support. These patients often show 
signs of malnouri shment and have not re­
sponded well to coaxed feeding. It may 
(continued on page 24) 
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be necessary to feed these dogs using a 
nasoesophagealor es phag al tube. In 
critical patients intra enous feeding is 
given to help an imals through a short 
time period unt il the chemotherapy takes 
effect. This i::; nnt complete nutritional 
support, nor is it mean t to be used as life 
support. It is providing adequate nutri­
tional care for a limited time to cancer 
patients who are unable to nourish them­
sel ves duri ng the treatment of their 
di sease . 
M.R. 
Canine Osteosarcoma 
Osteosarcoma is the most common 
primary bone tumor in dogs. accounting 
for some 85 percent of canine bone tu­
mors . VHUP clinical spec ia list Drs . 
Kim Cronin and Amy Kapatk in ex­
plained the disease process of - and 
treatments for - steosarcoma. 
The average Sleosarcoma patient is 
seven or eight years of age, al though 
dogs as young as six months old have 
been diagnosed with this cancer. It typi­
cally strikes large- and giant-breed dogs 
like great Danes, golden retrievers and 
German 'hepherds. Associated with high 
amounts of stn:ss on weight-bearing 
limbs, osteosarcoma is almost 500 times 
as likely to affec t dogs over 35 kg than 
dogs weighing less than 10 kg. 
Os teosarcoma::; tend to anchor them­
selves in areas of increased bone remod­
eling, said Dr. Cronin, lec turer in 
oncology. "Every time you have cell 
damage or increast!d turnover, the DNA 
is more likel to make a mistake when 
coding for new cells. which can lead to 
tumor formation ." So naturally, previous 
fractures and chronic bone infections are 
predisposing factors. These tumors are 
more likely to occur in the li mbs, par­
ticularly the forelim bs, which bear most 
of the body weight; other bones, such as 
the ribs and skull, can also be affected. 
Osteosarcoma is both locally invasive 
and metastatic. It infiltrat s the bone and 
weakens it. It then spreads throughout 
the body. The chief presenting signs for 
osteosarcoma are lameness and pain 
(which may be intermittent) , limb swell­
ings and pathologic fractures at the 
tumor site. 
Because osteosarcoma shares com­
mon clinical signs wi th other conditions 
like degenerati ve joint disease (arthritis), 
infectious diseases and other tumors of 
the bone (i.e. fibrosarcoma, chondrosar­
coma, hemangiosarcoma and synovial 
cell tumor), a thorough physical exam, 
radiographs and biopsy are used to make 
the fin al diagnosis. Ch st radiographs 
should be performed in dogs diagnosed 
with osteosarcoma. Accordi ng to Dr. 
Cronin, over 90 percent of afflicted dogs 
have pulmonary metastasis at the time of 
diagnosi , although lung nodu les may 
not yet be visib le radiographically. 
Because of its high metastatic poten­
tial, osteosarcoma carries a guarded 
prognosis. Most patients ventually die 
of meta ·tas is to the lungs or other or­
gans. The average surv ival time from the 
date of diagnosis is 8-12 months. Only 
20 percent of patients are alive two years 
after diagnosis. Without treatment, most 
patients succumb to the di sease within a 
couple of months. 
Treatment is aimed at removing neo­
pia tic sites and preventing further seed­
ing. If the tumor is on a leg, amputation 
is the usual course. "We must be ery ag­
gressive in our initial approach so we 
don't get regrowth ," said Dr. Kapatkin, 
assistant professor of orthopedics and 
neurosurgery. The leg i<.; typically disar­
ticulated at the coxofemoral (hip) or 
scapulohumeral (shoulder) joint. "Ampu­
tation is very cosmetic and most of our 
patients can ambulate well on three legs 
and are incredibly happy," said Dr. 
Kapatkin. 
Limb sparing is the other surgical ap­
proach. Here, the tumor is resected en 
bloc with 3-5 cm margins, and the gap is 
filled with bone graft or donor bone. Po­
tential complications include infection, 
implant failure and tumor recurrence. 
However, the survival rate is the same 
for limb-spari ng as for amputation. 
Surgery can be performed also to ex­
cise metastases. Prolonged survival rates 
have been achieved in cases where three 
or fewer nodules were present and sur­
vival until metastasis was diagnosed ra­
diographically was 300+ days, Dr. 
Kapatkin said. 
Radiation therapy can be potent in de­
stroying neoplastic cells at the primary 
tumor site and chemotherapy may be em­
ployed to prevent or delay metastasis. 
Several drugs - including carboplatin, 
cisplatin and doxorubicin, are part of the 
osteosarcoma chemotherapy protocol, 
which is typically initiated 10-14 days 
after surgery. Immunotherapy, which ac­
tivates the immune system to combat 
cancer cells, is part of newer treatment 
protocols. 
J.e 
Canine Brain Tumors 
Brain tumors in dogs are not infre­
quent. Nor are they untreatable. Drs. 
Charles Vite and Amy Kapatkin clarified 
the key issues revolving around brain tu­
mors in dogs and their surgical biopsy. 
According to Dr. Vile, post-doctoral 
fellow in neurology at VHUP, brain tu­
mors are a common cause of neurologi­
cal dysfunction in dogs over five years of 
age. Primary brain tur·lOr~; ;lrise from 
neuroepithelial (i.e. astrocytoma, 
oligodendrocytoma, choroid plexus neo­
plasm and ependymal tumors) and 
meningeal ti ssue (meningioma). Brain 
tumors can also arise secondarily from 
surrounding tissues like the nasal cavity 
or bone (i.e. nasal carcinoma, chondroma 
and osteosarcoma) , or originate from he­
matogenous metastasis from tumors else­
where in the body (i.e . malignant 
melanoma, hemangiosarcoma and lym­
phosarcoma). 
Cli nical signs of a brain tumor depend 
on the location of the mass. Tumors of 
the cerebrum and thalamus may result in 
sei7.ures and depression : tumors of the 
cerebellum and brain stem typically re­
sult in incoordination and cranial nerve 
deficits. "The clinical signs tell us what 
part of the brain is affected ," said Dr. 
Vite. 
A thorough neurological exam should 
be performed. Once the location of the 
lesion is determined based on the neuro­
logic signs, the lesion is then character­
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ized as either neoplastic, inflammatory, 
cerebrovascular or degenerative. Because 
nothing is pathognomonic for a brain tu­
mor except biopsy results, one must 
compile a list of differential diagnoses 
that can account for the clinical signs. 
The factors that go into ranking these 
differential diagnoses are patient signal­
ment (age, breed and sex), chronicity and 
progression of signs, evidence of focal or 
multifocal neurologic disease, and pres­
ence of other systemic disease. 
F or example, said Dr. Vite, the differ­
ential diagnoses for a six-year-old golden 
retriever presenting with a sudden onset 
of generalized seizures include: intracra­
nial tumor, encephalitis, metabolic dis­
ease and idiopathic epilepsy. Add to this 
the dog's history of increasing mental 
dullness. and idiopathic epilepsy moves 
further down on the lis~. Throw in the 
fact that the dog is blind in the right eye 
and has right-sided postural deficits and 
the clinical picture is now most closely 
referable to either a brain tumor or 
encephalitis. 
A cerebrospinal fluid (CSF) tap, titers 
to known organisms capable of causing 
encephalitis, and magnetic resonance im­
aging (MRI) of the brain can aid in dis­
tinguishing between these two possible 
causes . However, Dr. Vite added, defini­
tive diagnosis of a brain tumor requires 
biopsy of the mass. 
Once a brain tumor is tentatively di­
agnosed, surgical feasibility is then de­
termined. Surgical success depends on 
the type of tumor present and its loca­
tioll . said Dr. Kapalkin. assistant profes­
sor of orthoped ics and neurosurgery. 
Most meningiomas are treatable with 
su rgery and adjunctive therapy, increas­
ing a patient s's lifespan; p itui tary tu­
mors, on the other hand, are not easily 
treated. The cerebrum is the best location 
to have a tumor, she added. "We can re­
move a whole half of the cerebrum and 
you probably wouldn't notice a big dif­
ference in your pet." 
The three main surgical approaches 
are the lateral, transfrontal and suboc­
cipital entries. The lateral - or parietal 
- approach involves making a curved 
incision and elevating the muscles over 
the parietal bone. A hole is then drilled in 
the bone and the cerebrum is accessed. In 
the transfrontal approach, the frontal si­
nus is penetrated and the frontal bone is 
removed using a bone saw. The tumor is 
removed from the prefrontal area and the 
bone is replaced. The suboccipital ap­
proach, used to enter the cerebellum or 
brainstem. involves a midline inci,ion 
made at the caudal aspect of the skull. 
Care must be taken to avoid potentially 
lethal lacerat ion of the sinuses in this re­
gion. A fourth approach, the ventral ap­
proach, is made through the oral cavity. 
Used main ly to access pituitary 
microadenomas, this approach carries 
high ri sk of in fection. Treatment of pitu­
itary tumors may incorporate radiation as 
a substitute for - or adjunct to ­
surgery. 
In addition to sophisticated surgical 
techniques, Dr. Kapatkin credits ad­
vanced post-operative care with the high 
success rate for brain surgery. Intensive 
care. including fluids and ventilator 
therapy, is provided afte r ~u rgery to pre­
vent or rapidly respond to potential com­
plications, such as seizures, surges in 
intracranial pressure. and intracranial 
hemorrhage. Fortunately, most patients 
suffer no complications. I n fact, she said. 
"Seventy-five percent of pat ien ts we do 
brain surgery on literally eat dinner the 
same day of their surgery." 
I e 
Mammary Cancer 
Tumors of the canine mammary gland 
are common. They comprise 52% of all 
tumors in the intact female dog and oc­
cur most often between 10 and 11 years 
of age. The breeds most highly repre­
sented are spaniels, terriers. German 
shepherds as well as toy and miniature 
poodles. Mammary gland tumors are of­
ten associated with early estrogen expo­
sure. "The risk for tumor development is 
associated with estrogen exposure during 
the first few years of life and that has a 
significant importance when it comes to 
preventing these tumors" said Dr. Kari n 
Sorenmo, assistant professor of oncol­
ogy. When a dog is spayed before the 
Cl-'lr r n rE . 
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first estrus, she has a 0.5% chance of de­
veloping breast cancer later in life. If she 
is spayed before the second eslrus there 
is an 8% chance of deve loping breast 
cancer, and spaying a fter the third estrus 
- or any estrus therea fter - increases 
the like lihood of mammary cancer to 
26%. In dogs that were spayed in addi­
tion to having the tumor removed the 
median surv ival was 659 days. Whereas , 
dogs that were le ft intact afte r the ir treat­
ment surgery had a median survi val of 
only 198 days. 
The rel ationship between es trogen 
and mammary cancer in canines is also 
important because there are similarities 
with estrogen and breast cancer in 
women. Women with breast cancer are 
usually middle aged to older - the same 
age di.stribution seen in dogs. The most 
common types of tumors in dogs are the 
same as those found in women. Can ine 
estrogen positi ve tumors respond to hor­
monal lherapy by removing the ovaries. 
Estrogen po~ it ive tumors in women re­
spond to Tamoxifen which is an anti­
estrogen. Both dogs with mamm ary 
gland tumors and women with breast 
cancer can be treated very effectively if 
the tumors are small and there is no ev i­
dence of metastasi~. And both canine and 
human patients w ilh large primary tu­
mors or metastatic tumors are at high 
risk for dying from the d isease. HI think 
that dogs can provide some very interest­
ing and valuable models for this disease 
in women" sa id Dr. Sorenmo. 
It has beell reported [hal about half of 
the dogs wi th mammary gland tumors 
will actual ly have multiple masses . The 
caudal glands are affected more fre­
quently. Mammary tumors can feel firm, 
soft or thickened and vary widely in size. 
They may be ulcerated. infl amed or 
edematous and one can not determine if 
they are malignant or ben ign from these 
signs. "The good thing is that even 
though this is a very common type of tu­
mor in the in tact female dog, half are 
likely to be ben ign." To obta in a diagno­
sis, a wide-margin excisional is per­
formed if the surgical marg ins are clcan 
this is also the treatment of choice for the 
primary tumor. However. it is necessary 
(continued on page 26) 
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to first evaluate the patient's general 
health through blood analysis and to look 
for possible systemic spread of the can­
cer with chest radiographs. If there is 
lymph node involvement then the risk for 
developing distant metastasis in the 
lungs is much higher. 
Once the tumor type has been deter­
mined from the biopsy, and the extent of 
disease has been determined by one 
work-up, it is possible to suggest an out­
come as well as an appropriate treatment. 
Several good retrospective studies indi­
cate that survival rates are higher for 
dogs with small tumors . Tumors that are 
made up of well differentiated cells are 
likely to have a better prognosis than tu­
mors that are anaplastic and have a high 
mitoti c index. Invasive tumors can be 
more likely to metastasize than encapsu­
lated ones. In general, tumors that have 
metastasized, have a much poorer 
prognosis. 
The best treatment option is surgical 
resection. If the tumor is small it can be 
effectively treated with a lumpectomy or 
a mastectomy. A large tumor or tumors in 
multiple glands require a broad approach 
- regional or radical mastectomy - in 
order to remove all the malignant tissues 
at the primary site. It is thought that the 
progression of thes tumors is dependent 
upon the presence of estrogen and an 
ovariohysterectomy - removal of the 
ovaries - makes it less likely that the 
tumor will continue to grow. Chemo­
therapy is indicated in dogs that have 
mult iple negative prognostIc factors and 
lymph node metastasis . More work needs 
to be undertaken in thi s area because 
there are no controlled studies to docu­
ment the effeclivent:SS of adjuvant che­
motherapy after surgery in dogs with 
high risk mammary gland tumors. 
The owner has a significant role in 
preventing canine mammary gland tu­
mors through early detection. All tumors 
start out small and often appear insidi­
ously. Therefore. it is important for the 
owner to either examine their dog's 
glands or provide for regul ar veterinary 
check ups. There is one retrospective 
study from the University of Pennsylva­
nia that found 95% of dogs with mam­
mary gland tumors were likely to be 
overweight during their first year of life. 
By feeding a balanced diet, spaying early 
and providing regular examination of the 
mammary glands, the pet owner may sig­
nificantly reduce the chances of tumor 
development. All tumors should be re­
moved and biopsied because early treat­
ment is crucial for a good outcome. Do 
not watch and wait. 
M.R. 
From the Laboratory Bench 
to the Patient's Bedside 
New research in angiogenesi s - or 
neovascularization - and its regulation 
has led to the discovery that inhibitors 
of this process are potent and promising 
anti-tumor drugs. "While this work is in 
its early stages we are very hopeful that 
we can make a contribution to thi s 
growing field" said Dr. Andrei 
Tikhonenko, assistant professor of pa­
thology. 
In the normal adult body there is 
very little angiogenesis apart from 
wound healing and menstrual cycling. 
When angiogenesis occurs, a new blood 
vessel sprouts from the pre-existing 
one. The membrane surrounding the 
original vessel dissociates and the en­
dothelial cells migrate and undergo self 
proliferation. Cancer biologists and doc­
tors have known for years that almost 
all malignant tumors are heavily vascu­
larized. The tumor is penetrated by a 
tightly knit network of sma ll blood cap­
illaries which supply blood and feed the 
tumor with oxygen and nutrients . If an­
giogenesis can be controlled then it may 
be possible to cut off the blood supply 
to the tumor and prevent its growth. 
This concept is attracti ve because tumor 
cells are capable of rapidly accumulat­
ing mutation and becoming resistant to 
chemotherapy and other therapies. 
Within the last three to four years 
some of the molecules which are re­
sponsible for endothelial cell growth 
were identified. Most cells in the body 
- including tumor cells - secrete both 
inhibitors and activators of angiogen­
esis. However, normal ti ssues secrete 
more repressors than activators while 
tumor cell s secrete either more activa­
tors or less repressors and turn the an­
giogenic "switch" on. Some of the 
molecules that have been identified are: 
Vascular Endothelial Growth Factor ­
the most potent activator of angiogen­
esis - as well as some inhibitors such 
as Thrombospondin 1. There are other 
even more potent inhibitors such as 
some members of the Interleukin family 
and Angiostatin, and the most recent ad­
dition to the list is a protein called 
Endostatin. 
In a recent study published in Nature 
magazine, a purified form of Endostatin 
- a very potent inhibitor of angiogen­
esis - was used. Tumors treated with 
Endostatin regressed very rapidly. The 
tumor cell s remained, but, in the ab­
sence of blood vasculature they did not 
grow and slowly regressed. When the 
therapy was discontinued the tumor 
cell s regrouped and formed another tu­
mor. If Endostatin therapy was given 
again, the tumor regressed again but 
grew back as soon as therapy was 
stopped. Surprisingly, after twelve to 
fourteen cycles the ability of the tumor 
to grow back was lost. Still, the problem 
is that Endostatin therapy is too costly 
for prolonged use. 
One type of tumor may be more sen­
s itive to Endostatin - tumors of the en­
dotheli a l cells themselves. In canines 
this tumor is often known as heman­
giosarcoma . Hemangiosarcoma is a very 
malignant tumor and is capable of me­
tas tasis and dissemination. Thi s tumor is 
often fatal for the dog. It most com­
monly affects the spleen or the right 
atrium of the heart, particularly in 
German shepherds. Hemangiosa rcomas 
are comprised of chaotically arranged 
endothelial cells and may not respond to 
all of the inhibitors of angiogenesi s in 
the same way that normal endothelia l 
cells do. "We are poised to test the nu­
merous inhibitors of angiogenesis and 
measure their ability to inhibit the 
growth and viability of hemangio­
sarcoma cells," explained Dr. 
Tikhonenko. M.R. 
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